Evidence map›Paper›PMID 39553416›Full record

ArticleThe Lancet regional health. Western Pacific2024

Impact of time to antibiotics on clinical outcome in paediatric febrile neutropenia: a target trial emulation of 1685 episodes.

Gabrielle M Haeusler, S Ghazaleh Dashti, Fiona James, Franz E Babl, Meredith L Borland, Julia E Clark, Bhavna Padhye, Heather Tapp, Frank Alvaro, Trisha Soosay Raj and 13 more

Abstract read
In one paragraph

Article in The Lancet regional health. Western Pacific, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Gabrielle M HaeuslerDepartment of Infectious Diseases, Royal Children's Hospital, Parkville, Victoria, Australia.
S Ghazaleh DashtiMurdoch Children's Research Institute, Parkville, Victoria, Australia.
Fiona JamesMurdoch Children's Research Institute, Parkville, Victoria, Australia.
Franz E BablMurdoch Children's Research Institute, Parkville, Victoria, Australia.
Meredith L BorlandEmergency Department, Perth Children's Hospital, Nedlands, Western Australia, Australia.
Julia E ClarkInfection Management, Queensland Children's Hospital, Brisbane, Queensland, Australia.
Bhavna PadhyeCancer Centre for Children, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
Heather TappDepartment of Oncology, Women's and Children's Hospital, Adelaide, South Australia, Australia.
Frank AlvaroChildren's Cancer and Blood Disorders, John Hunter Children's Hospital, Newcastle, New South Wales, Australia.
Trisha Soosay RajChildren's Health Queensland Clinical Unit, University of Queensland, Queensland, Australia.
Thomas WalwynDepartment of Oncology, Perth Children's Hospital, Perth, Western Australia, Australia.
David S ZieglerChildren's Cancer Institute, Lowy Cancer Centre, UNSW Sydney, Kensington, NSW, Australia.
Leanne SuperChildren's Cancer Centre, Royal Children's Hospital, Parkville, Victoria, Australia.
Lisa HallNHMRC National Centre for Infections in Cancer, Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Daniel K YeohMurdoch Children's Research Institute, Parkville, Victoria, Australia.
Coen ButtersMurdoch Children's Research Institute, Parkville, Victoria, Australia.
Brendan McMullanNHMRC National Centre for Infections in Cancer, Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Diane M T HannaMurdoch Children's Research Institute, Parkville, Victoria, Australia.
Richard De Abreu LourencoCentre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, New South Wales, Australia.
Monica A SlavinDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Bob PhillipsCentre for Reviews and Dissemination and Hull-York Medical School, York, UK.
Karin A ThurskyDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Australian PICNICC and There is No Place Like Home study groups

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prompt antibiotic administration for febrile neutropenia (FN) is standard of care, and targets of time to antibiotics (TTA) <60 min are common. We sought to determine the effect of TTA ≥60 versus <60 min on adverse outcomes (intensive care unit (ICU) admission or death) in children with cancer and FN. Effect modification by a decision rule that predicts infection (AUS-rule) and bacteraemia were also investigated. Methods: The prospective, multi-centre (n = 8), Australian PICNICC study dataset was analysed. To control for confounding, we used outcome regression adjusted for propensity score modelled as restricted cubic spline with two degrees of freedom. The propensity score was estimated from a logistic regression model for the exposure on the confounders, identified Findings: 1685 FN episodes in 976 patients were included. Median TTA was 53 min (IQR 37-77 min, 1542 (92%) <120 min). An adverse outcome occurred in 43 (2.6%) episodes (39 ICU; 5 deaths). The confounder-adjusted point estimate suggested a lower risk for adverse outcome associated with TTA ≥60 min (RR 0.62, 95% CI 0.32-1.21), but the wide 95% CI precluded definitive judgement about strength and direction of the effect (unadjusted RR 0.52; 95% CI 0.26, 1.05). Similarly, although the point estimates were suggestive of a null association or reduced risk for adverse outcome associated with TTA ≥60 min for all comparisons across bacteraemia or AUS-rule strata, the 95% CIs were imprecise. Interpretation: For children with FN, there was no definite evidence that TTA ≥60 min from hospital triage (but within 2 h), increased risk of adverse outcome or prolonged hospital admission. This study has important implications for FN TTA mandates, suggesting a more nuanced approach is required. Funding: National Health and Medical Research Council and Medical Research Future Fund.

Indexed as

Children with cancerFebrile neutropenia (FN)Time to antibiotics (TTA)

Identifiers

PMID39553416
PMCPMC11566883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.